niceritrol has been researched along with Hyperlipoproteinemia Type III in 1 studies
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.
Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kibata, M | 1 |
| Ishida, M | 1 |
| Asano, K | 1 |
| Uehara, H | 1 |
| Saito, K | 1 |
| Fuchimoto, T | 1 |
| Ugaki, K | 1 |
| Murakami, H | 1 |
| Matoba, K | 1 |
| Kotakemori, Y | 1 |
| Shirai, K | 1 |
| Yoshioka, H | 1 |
| Nanba, M | 1 |
| Yasuda, M | 1 |
| Ishizaki, M | 1 |
| Kitagawa, N | 1 |
| Ikejiri, K | 1 |
| Inohara, R | 1 |
| Lee, BJ | 1 |
| Saino, S | 1 |
| Sakado, J | 1 |
| Matuzaka, H | 1 |
| Numata, K | 1 |
| Mandai, M | 1 |
| Miyake, K | 1 |
| Nakamura, K | 1 |
1 other study available for niceritrol and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
Topics: Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hypolipide | 1980 |